CAR NKT cells get early proof of concept with Kuur readout

Kuur’s early clinical NKT cell efficacy data add to a growing body of evidence that cell types beyond effector T cells hold promise as cancer therapies.

Kuur Therapeutics, which re-launched and rebranded from Cell Medica Inc. last year, shared early interim clinical proof-of-concept data for its autologous and allogeneic CAR NK T cell technologies...